Daniel F. Ortwine

4.7k total citations
64 papers, 2.6k citations indexed

About

Daniel F. Ortwine is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Daniel F. Ortwine has authored 64 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 23 papers in Organic Chemistry and 11 papers in Oncology. Recurrent topics in Daniel F. Ortwine's work include Computational Drug Discovery Methods (10 papers), Quinazolinone synthesis and applications (8 papers) and Synthesis and Biological Evaluation (7 papers). Daniel F. Ortwine is often cited by papers focused on Computational Drug Discovery Methods (10 papers), Quinazolinone synthesis and applications (8 papers) and Synthesis and Biological Evaluation (7 papers). Daniel F. Ortwine collaborates with scholars based in United States, United Kingdom and France. Daniel F. Ortwine's co-authors include A.G. Pavlovsky, Bruce D. Roth, Drago R. Sliskovic, Elizabeth A. Lunney, Christopher F. Bigge, Leslie M. Werbel, Donald Hupe, Richard D. Dyer, Peter A. Boxer and Roger S. Newton and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Daniel F. Ortwine

64 papers receiving 2.5k citations

Peers

Countries citing papers authored by Daniel F. Ortwine

Since Specialization

Citations

This map shows the geographic impact of Daniel F. Ortwine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel F. Ortwine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel F. Ortwine more than expected).

Fields of papers citing papers by Daniel F. Ortwine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel F. Ortwine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel F. Ortwine. The network helps show where Daniel F. Ortwine may publish in the future.

Co-authorship network of co-authors of Daniel F. Ortwine

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel F. Ortwine. A scholar is included among the top collaborators of Daniel F. Ortwine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel F. Ortwine. Daniel F. Ortwine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors 2023 ·eLife ·Marc Kschonsak, Christine C. Jao, Christopher P. Arthur, Alexis Rohou, Philippe Bergeron, Daniel F. Ortwine, Steven J. McKerrall, David H. Hackos, Lunbin Deng, Jun Chen, Tianbo Li, Peter S. Dragovich, Matthew Volgraf, Matthew Wright, Jian Payandeh, Claudio Ciferri, John C. Tellis	17
2	Measuring experimental cyclohexane-water distribution coefficients for the SAMPL5 challenge 2016 ·Journal of Computer-Aided Molecular Design ·Ariën S. Rustenburg, (unknown), Baiwei Lin, Jianwen A. Feng, Daniel F. Ortwine, David L. Mobley, John D. Chodera	37
3	Enabling drug discovery project decisions with integrated computational chemistry and informatics 2016 ·Journal of Computer-Aided Molecular Design ·Vickie Tsui, Daniel F. Ortwine, Jeffrey M. Blaney	5
4	An integrated suite of modeling tools that empower scientists in structure- and property-based drug design 2015 ·Journal of Computer-Aided Molecular Design ·Jianwen A. Feng, Ignacio Aliagas, Philippe Bergeron, Jeff Blaney, Erin K. Bradley, Michael F. T. Koehler, Man‐Ling Lee, Daniel F. Ortwine, Vickie Tsui, Johnny C. Wu, Alberto Gobbi	14
5	A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery 2015 ·Journal of Computer-Aided Molecular Design ·Ignacio Aliagas, Alberto Gobbi, Timothy P. Heffron, Man‐Ling Lee, Daniel F. Ortwine, Mark Zak, S. Cyrus Khojasteh	23
6	Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Jason D. Burch, Steven Magnuson, Daniel F. Ortwine, Yuan Chen, (unknown), Xiao Ding, Charles Eigenbrot, Adam R. Johnson, Marya Liimatta, Yichin Liu, Steven Shia, Xiaolu Wang, Lawren C. Wu, Zhonghua Pei	13
7	A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Wendy Lee, Daniel F. Ortwine, Philippe Bergeron, Kevin Lau, (unknown), Shiva Malek, Jim Nonomiya, Zhonghua Pei, Kirk Robarge, Stephen Schmidt, Steve Sideris, Joseph P. Lyssikatos	26
8	The evaluation of 25 chiral stationary phases and the utilization of sub-2.0μm coated polysaccharide chiral stationary phases via supercritical fluid chromatography 2013 ·Journal of Chromatography A ·(unknown), Mengling Wong, Ignacio Aliagas, Daniel F. Ortwine, (unknown), Donald E. Schmidt, (unknown)	37
9	Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability 2013 ·Journal of Biological Chemistry ·Benjamin Lauffer, Robert Mintzer, Rina Fong, Susmith Mukund, Christine Tam, Inna Zilberleyb, (unknown), (unknown), Grazyna Fedorowicz, Roxanne O. Vallero, Daniel F. Ortwine, Janet L. Gunzner, Zora Modrušan, Lars Neumann, Christopher M. Koth, Patrick J. Lupardus, Joshua S. Kaminker, Christopher E. Heise, Pascal Steiner	338
10	Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC 2012 ·Bioorganic & Medicinal Chemistry Letters ·Joseph S. Warmus, Cheryl L. Quinn, Clarke Taylor, Sean T. Murphy, Timothy A. Johnson, Chris Limberakis, Daniel F. Ortwine, Joel C. Bronstein, (unknown), John D. Knafels, Sandra Lightle, Igor Mochalkin, Roger J. Brideau, Terry Podoll	28
11	Quinazolinones and Pyrido[3,4- d ]pyrimidin-4-ones as Orally Active and Specific Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis 2008 ·Journal of Medicinal Chemistry ·Jie Jack Li, (unknown), Adam R. Johnson, Amy Bunker, Patrick O’Brien, (unknown), Daniel F. Ortwine, (unknown), Vijay Baragi, Kenneth S. Kilgore, Richard D. Dyer, Dong‐Wook Han	74
12	Effect of Species Differences on Stromelysin-1 (MMP-3) Inhibitor Potency 1999 ·Journal of Biological Chemistry ·Linda L. Johnson, Dirk A. Bornemeier, (unknown), Jing Chen, A.G. Pavlovsky, Daniel F. Ortwine	12
13	Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988 1996 ·Bioorganic & Medicinal Chemistry ·Corinne E. Augelli‐Szafran, (unknown), Clare O. Kneen, Daniel F. Ortwine, Martyn C. Pritchard, (unknown), Bruce D. Roth, Bharat K. Trivedi, David R. Hill, Nirmala Suman‐Chauhan, Louise Webdale	12
14	Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: characterization of .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity 1995 ·Journal of Medicinal Chemistry ·Christopher F. Bigge, Thomas C. Malone, Peter A. Boxer, (unknown), Daniel F. Ortwine, (unknown), (unknown), (unknown), Susan A. Borosky	50
15	Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists 1992 ·Journal of Medicinal Chemistry ·Daniel F. Ortwine, Thomas C. Malone, Christopher F. Bigge, James T. Drummond, Christine Humblet, Graham Johnson, (unknown)	45
16	Exploration of N-phosphonoalkyl-, N-phosphonoalkenyl-, and N-(phosphonoalkyl)phenyl-spaced .alpha.-amino acids as competitive N-methyl-D-aspartic acid antagonists 1992 ·Journal of Medicinal Chemistry ·Christopher F. Bigge, Graham Johnson, Daniel F. Ortwine, James T. Drummond, (unknown), (unknown), Linda L. Coughenour, F Marcoux, Albert W. Probert	45
17	Antimalarial drugs. 64. Synthesis and antimalarial properties of 1-imino derivatives of 7-chloro-3-substituted-3,4-dihydro-1,9(2H,10H)-acridinediones and related structures 1992 ·Journal of Medicinal Chemistry ·S. Kesten, (unknown), J. Hung, Dennis J. McNamara, Daniel F. Ortwine, (unknown), Leslie M. Werbel	49
18	Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus 1991 ·Journal of Medicinal Chemistry ·Bruce D. Roth, C. John Blankley, Alexander Chucholowski, Erika Ferguson, M. L. HOEFLE, Daniel F. Ortwine, Roger S. Newton, Catherine Sekerke, Drago R. Sliskovic, Michael Wilson	151
19	Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipoxygenase and cyclooxygenase inhibitors 1991 ·Journal of Medicinal Chemistry ·Darren Flynn, Thomas R. Belliotti, Amal M. Boctor, D. T. CONNOR, Catherine R. Kostlan, D E Nies, Daniel F. Ortwine, Denis J. Schrier, Jagadish C. Sircar	83
20	Evaluation and synthesis of amino-hydroxy isoxazoles and pyrazoles as potential glycine agonists 1989 ·Journal of Medicinal Chemistry ·James T. Drummond, Graham D. Johnson, (unknown), Daniel F. Ortwine, Robert F. Bruns, (unknown)	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact